Alivus Life Sciences to Acquire 76% Stake in IQGEN-X Pharma for ₹9.12 Cr

Alivus Life Sciences Limited announced its Board of Directors has approved the acquisition of a 76% stake in IQGEN-X Pharma Private Limited for an aggregate consideration of approximately ₹9.12 crores. The acquisition aims to expand Alivus's offerings in the API and CDMO space by integrating IQGEN-X Pharma's formulation development capabilities for oral solids, sterile injectables, and ophthalmic solutions. The transaction is expected to be completed by December 6, 2026, subject to customary closing conditions. IQGEN-X Pharma reported a turnover of INR 348 Lacs for the financial year ended March 31, 2026. This acquisition is not considered a related party transaction.